​​Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia​

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and ...

Related Keywords

Ingelheim ,Rheinland Pfalz ,Germany ,Quan Dong Nguyen ,Ulrike Graefe Mody ,Boehringer Ingelheim ,Animal Health ,Head Of Retinal Health At Boehringer Ingelheim ,Association For Research ,Pediatrics At Stanford School Of Medicine ,Byers Eye Institute ,Stanford School ,Coordinating Investigator ,Retinal Health ,Human Pharma ,Corporate Headquarters ,Ophthalmol Vis Sci ,